International Journal of Clinical Research

Objective Chinas novel coronavirus pneumonia was treated novel coronavirus pneumonia patients with different doses of COVID-19 inactivated vaccine. Methods: in 2020, Chibi City, according to the current address, was collected from the new crown pneumonia patients reported by the China Disease Control and prevention reporting information management system, and the 84 people who voluntarily accepted the care rehabilitation project and signed informed consent were included in the study. A novel coronavirus pneumonia vaccine was inoculated and the IgM and IgG levels of COVID-19 antibodies were tested. The average level of 1 and 2 IgG antibodies tested was tested by T. Results: the IgG antibody level of 58 people inoculated with 1 doses of COVID-19 vaccine ranged from 1.71 to 8.61, with a mean of 6.56±1.68. The 2 doses of COVID-19 vaccine inoculated with 22 persons and the level of COVID-19 IgG antibody ranged from 0.29 to 8.56, the mean value was 5.71 ±2.35. After T test, t=0.72 P > 0.05, there was no statistical difference in IgG level between the two groups. Conclusion: 1. Novel coronavirus pneumonia patients who received COVID-19 inactivated vaccine only need 1 doses of inoculation, and no need to inoculate 2 doses. 2. Some patients who did not receive COVID-19 vaccine were able to maintain the level of IgG antibody for 1 years and 7 months.

Novel Coronavirus Pneumonia; Cured Patients; Vaccination; Antibody Level